预约演示
更新于：2025-10-29
Atrasentan Hydrochloride
盐酸阿曲生坦
更新于：2025-10-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2025-04-02), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、特殊审批 (美国)、附条件批准 (中国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C29H38N2O6 |
InChIKeyMOTJMGVDPWRKOC-QPVYNBJUSA-N |
CAS号173937-91-2 |
关联
25
项与 盐酸阿曲生坦 相关的临床试验NCT06952426
A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
NCT05834738
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)
JPRN-jRCT2071210028
A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function - The ALIGN Study
100 项与 盐酸阿曲生坦 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿曲生坦 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿曲生坦 相关的专利（医药）
登录后查看更多信息
475
项与 盐酸阿曲生坦 相关的文献（医药）2025-10-01DRUGS
Atrasentan: First Approval
Review
作者: Keam, Susan J
Atrasentan (VANRAFIA®), a potent, highly selective, orally administered endothelin type A (ETA) receptor antagonist, is in development by Novartis for the treatment of glomerular disease. In April 2025, atrasentan was approved in the USA (under accelerated approval based on a reduction in proteinuria) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. It has not been established whether atrasentan slows kidney function decline in patients with IgAN. This article summarizes the milestones in the development of atrasentan leading to this first approval for the reduction of proteinuria in adults with primary IgAN at risk of rapid disease progression.
2025-10-01Kidney Medicine
IgA Nephropathy: An Overview of the Clinical Trials
Review
作者: Abdipour, Amir ; Gholizadeh Ghozloujeh, Zohreh ; Selvaskandan, Haresh ; Norouzi, Sayna ; Wiegley, Nasim ; Lerma, Edgar ; Gaytan, Jorge ; Garcia-Rivera, Alejandro
IgA nephropathy (IgAN) is characterized by the deposition of poorly-O-galactosylated IgA1 (also referred to as galactose-deficient IgA1 or gd-IgA1) containing immune complexes in the glomerular mesangium. This triggers a variable degree of glomerular inflammation that leads to progressive kidney damage and often kidney failure. The acceptance of proteinuria reduction as a reasonably likely surrogate end point for treatment effects on progression to kidney failure has led to many clinical trials evaluating novel and repurposed therapies for IgAN. New treatments leverage different aspects of IgAN pathophysiology, including the modulation of mucosal immunity, mechanisms of B-cell activation, and complement activity. The approval of the first treatments evaluated specifically for IgAN (including delayed-release budesonide, sparsentan, atrasentan, and iptacopan) represent meaningful advancements in the management landscape, and promisingly, many more treatments seem poised to arrive. This review compiles a list of current active trials for IgAN and highlights the necessity for ongoing research to optimize therapeutic strategies to further improve outcomes for those living with IgAN.
2025-04-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Pharmacoinformatics-based prediction of Checkpoint kinase-1 inhibitors from Momordica charantia Linn. for cancer
Article
作者: Ala, Chandu ; Kunjiappan, Selvaraj ; Murugesan, Sankaranarayanan ; Pandian, Sureshbabu Ram Kumar ; Haripriya, Subramanian ; Vijayalakshmi, Muniyandi ; Pavadai, Parasuraman
Checkpoint kinase 1 (Chk-1), a serine/threonine kinase family protein, is an emerging target in cancer research owing to its crucial role in cell cycle arrest. Therefore, we aimed to predict potential Chk-1 inhibitors from Momordica charantia Linn., using high-throughput molecular docking. We used a graph theoretical network approach to determine the target protein, Chk-1. Among 86 compounds identified from M. charantia L., five molecules such as α-spinasterol (-9.7 kcal × mol-1), stigmasterol (-9.6 kcal × mol-1), stigmasta-7,22,25-trienol (-9.5 kcal × mol-1), campesterol (-9.5 kcal × mol-1), and stigmasta-7,25-dien-3beta-ol (-9.5 kcal × mol-1) and standard drug CCT245737 (-8.3 kcal × mol-1) displayed highest binding affinity with Chk-1. Besides, pharmacokinetic studies have demonstrated the non-toxic and drug-like properties of these compounds. Furthermore, molecular dynamics (MD) simulation studies confirmed the strong intermolecular interactions and stability of the compounds with Chk-1. The estimation of binding free-energy derived from molecular docking was fully recognized by the Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) produced from the MD simulation paths. Altogether, these five compounds may serve as effective inhibitors of Chk-1, thereby could be used to develop new medications for cancer treatment.
337
项与 盐酸阿曲生坦 相关的新闻（医药）2025-10-27
·短话说肾
临床结果临床研究抗体药物偶联物
2025-10-27
·短话说肾
临床研究临床终止
2025-10-27
·制药网
并购siRNA专利到期
100 项与 盐酸阿曲生坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 免疫球蛋白a肾病 | 美国 | 2025-04-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病肾脏病 | 临床3期 | 美国 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 日本 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 阿根廷 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 澳大利亚 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 比利时 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 巴西 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 加拿大 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 智利 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 捷克 | 2013-06-12 | |
| 2型糖尿病肾脏病 | 临床3期 | 丹麦 | 2013-06-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 3,668 | 遞製鬱糧製壓遞艱顧鏇(衊窪獵襯範膚遞鹽夢鬱) = Atrasentan showed greater kidney protection in female than in male participants but also induced more heart failure events in the female participants 壓構選膚襯願窪願夢築 (醖觸憲積鏇艱糧廠齋壓 ) | 积极 | 2024-12-11 | |||
临床3期 | 270 | 衊鑰廠衊觸艱艱糧醖壓(糧鬱鹹鏇鏇糧糧鑰選範) = 鏇夢遞夢積蓋遞醖觸艱 積構顧觸顧鬱糧醖鹽襯 (築膚築窪糧膚遞窪衊憲, -44 ~ -32) | 积极 | 2024-10-25 | |||
Placebo | 衊鑰廠衊觸艱艱糧醖壓(糧鬱鹹鏇鏇糧糧鑰選範) = 鑰願憲夢淵蓋衊淵膚選 積構顧觸顧鬱糧醖鹽襯 (築膚築窪糧膚遞窪衊憲, -12 ~ 7) | ||||||
临床3期 | 1,834 | 繭選獵願鹹蓋鹹遞積衊(鏇鹽鹹糧糧顧範鹹獵遞) = 鬱築憲鑰獵壓憲齋夢醖 繭襯憲襯膚齋獵簾糧遞 (壓窪糧憲鑰簾蓋顧鏇蓋, 0.72 ~ 0.93) | 积极 | 2023-12-01 | |||
Placebo | 繭選獵願鹹蓋鹹遞積衊(鏇鹽鹹糧糧顧範鹹獵遞) = 窪夢醖鹹廠選範製餘簾 繭襯憲襯膚齋獵簾糧遞 (壓窪糧憲鑰簾蓋顧鏇蓋 ) | ||||||
临床3期 | - | 淵積鑰積蓋壓鹹鏇膚鏇(願範夢膚襯網壓積獵繭) = The study met its primary efficacy endpoint at the 36-week interim analysis, with atrasentan demonstrating superiority versus placebo with a clinically meaningful and highly statistically significant reduction in proteinuria (protein in urine) in patients with IgAN receiving supportive care (maximally tolerated and stable dose of a renin-angiotensin system [RAS] inhibitor). 壓糧築顧憲襯遞壓壓齋 (鏇獵鹽廠鹹鏇鏇艱壓鏇 ) 达到 | 积极 | 2023-10-30 | |||
Placebo | |||||||
临床2期 | 2型糖尿病肾脏病 PCSK9 | - | Atrasentan 0.75mg/d | 築夢簾淵艱選夢齋窪簾(膚鏇願選鬱膚築鹹範築) = 醖憲膚築醖鏇夢鏇顧膚 選夢鏇選顧鏇衊艱艱積 (糧壓鑰簾築鹹鏇構網願, -52.7 ~ 1.0) | 积极 | 2022-11-05 | |
临床2期 | - | 醖簾遞觸鬱鹹簾夢糧構(願選網夢壓廠範齋醖範) = 齋糧繭鬱醖鏇壓窪繭衊 艱齋糧鬱構構膚願築簾 (廠醖遞鹹顧範繭襯遞鹽, 39.8 ~ 58.3) | 积极 | 2022-11-03 | |||
临床2期 | 20 | 廠鑰鏇壓遞製繭獵繭膚(網鹹觸網願壓憲糧蓋築) = 鹹憲夢憲廠繭網淵蓋選 願網膚簾衊壓製遞選鏇 (夢製鹽願獵餘壓遞蓋淵 ) 更多 | 积极 | 2022-11-01 | |||
临床3期 | 5,107 | 積淵廠範築憲窪憲衊獵(廠獵襯築鏇範蓋餘鹽觸): HR = 1.39 (95% CI, 0.97 ~ 1.99), P-Value = 0.072 | 积极 | 2022-07-01 | |||
Placebo | |||||||
临床2期 | 17 | 構構簾鑰構顧築醖蓋選(憲鑰範廠壓選顧鬱鏇襯) = 膚範積鹽願獵餘壓淵鑰 獵廠願觸觸餘選艱壓糧 (醖糧繭選糧膚餘齋艱壓, 29.0 ~ 55.2) | 积极 | 2022-05-03 | |||
临床3期 | 3,668 | 選廠壓鬱醖鏇築醖壓選(憲鬱簾築觸憲鹽蓋製夢): hazard ratio = 1.39 (95% CI, 0.97 ~ 1.99) 更多 | - | 2021-12-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用